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ABSTRACT
Objective: The purpose of this research is to determine the effect of depot medroxyprogesterone acetate (DMPA) on the levels of follicle-stimulating 
hormone (FSH), progesterone, estradiol, and calcium.
Methods: This was a cross-sectional study, this study was conducted in the region of Lubuk Buaya Health Care and Andalas Health Care on September–
November 2017. Examination of FSH, progesterone, and estradiol levels was performed in the Laboratory Biomedicine, Faculty of Medicine, Andalas 
University by ELISA method, and the examination of calcium level was performed in Laboratory Biochemistry, Faculty of Medicine, Andalas University 
by calcium Arsenazo method. Then, the data were analyzed by Kolmogorov–Smirnov and independent t-test.
Results: This study showed that there was a significant difference of FSH, progesterone, estradiol, and calcium levels on KB DMPA acceptors and non-
acceptors with p<0.05.
Conclusion: The use of contraception DMPA has the effect on the levels of FSH, progesterone, estradiol, and calcium in the blood.
Keywords: Depot medroxyprogesterone acetate, Progesterone, Estradiol, Calcium.
INTRODUCTION
Indonesia is the fourth most populous country in the world with annual 
population growth rate of 1.38%. By 2020, it was estimated that the 
population would be increased by 32.6 million so it would be affect 
maternal mortality [3,5].
Contraception in terms of health is an attempt to reduce maternal 
mortality and morbidity by controlling the rate of population growth so 
as to improve maternal and child health [12].
Depot medroxyprogesterone acetate as a contraceptive in an aqueous 
suspension injection is given by intramuscular for prolonged action. It 
was given at a dose of 150 mg every 12 weeks [11].
Substances major metabolite of depot medroxyprogesterone acetate 
(DMPA) is 6α-methyl-6β, 17α, 21-trihydroxy-4-pregnene-3, 20-dione-
17-acetate which secreted through urine. Approximately 90–95% DMPA 
binds to protein, namely albumin, and is metabolized in the liver. DMPA 
will be conjugated with glucuronic acid and sulfate which is excreted 
through urine. After DMPA was injected intramuscularly, the MPA is slowly 
released from the injection site from the low level to persistently enter the 
circulation and can be detected in the serum after 30 min of injection [20].
The use of hormonal contraceptives such as DMPA could affect the 
gonadotropin hormone (GnRH) produced in the hypothalamus, thereby 
suppressing luteinizing hormone (LH) spikes. LH is suppressed in 
higher levels than follicle-stimulating hormone (FSH). Decreased LH 
levels will inhibit follicle development so as not to ovulate, thereby 
causing low estrogen and progesterone levels [10,15].
The effects of DMPA mechanisms which suppress ovulation result in a 
hypoestrogenic environment that will negatively impact the absorption 
of calcium in the intestine, resulting in the disturbed bone mineral 
formation [15].
Decreased estradiol levels will stimulate the release of mediators 
affecting the activity of cells which function as bone breakers, and 
this will increase the risk of osteopenia and osteoporosis. Estrogen 
deficiency will increase the activity of the cells that function as bone 
breakers causing reduced calcium deposits in the bone [13,19].
Cundy et al. research states that when DMPA is given in sufficient 
doses to induce hypogonadism, the use of MPA can be associated 
with significant initial trabecular bone loss, which is a consequence of 
estrogen deficiency [7].
Akinloye et al. stated that injected contraception plays a role in calcium 
homeostasis which results in an increased effect of calcium mobilization 




This was a cross-sectional study. Data were collected at 1 time, where 
data collection and sampling of blood samples are carried out at the 
same time. Samples taken were acceptors of DMPA contraception with 
2–4 years of use and non-acceptor mothers contraception as control.
Study area
This study was conducted in the Work Area of Lubuk Buaya Health 
Centre and Andalas Health Centre, Padang city. Examination of FSH, 
progesterone, and estradiol levels was done in Biomedical Laboratory 
of Andalas University, Faculty of Medicine by ELISA method, and 
calcium examination was done in Biochemistry Laboratory of Faculty 
of Medicine, Andalas University by calcium Arsenazo method.
Inclusion and exclusion criteria
The sample in this study was DMPA contraceptive participants and 
mothers of non-contraceptive acceptors with a reproductive age of 
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20–40 years. For DMPA users with criteria inclusion was already 
using DMPA contraception for 2–4 years and was normal body mass 
index (BMI). Criteria for the exclusion of smokers and heavy drinkers 
suffering from bone disease and using drugs that could affect bone 
mineral density.
Different from the results of the study Kisok and Hyejin who stated 
that oral contraceptive use was not related to BMI, household income, 
drinking alcohol, or regular exercise. in this study, the above criteria 
were taken into consideration because it could influence hormone and 
calcium levels to be examined [14].
Sample size determination
Samples taken must be the same between the two groups in that the 
results of the study were more significant. The sample calculation 
formula used is a numerical formula of two independent populations. 
The total sample in this study was 66 people.
Sampling procedure
The sample selection was done by consecutive sampling. All subjects 
who came in sequence and met the inclusion criteria were included in 
the study until the required number of subjects was met.
Data collection process
This research was conducted from September 13 to November 2, 2017 
in the working area of Lubuk Buaya Padang Health Center, the work 
area of Padang Andalas Health Center, the Biomedical Laboratory 
of Andalas University and the Biochemistry Laboratory of Andalas 
University. This study was conducted on 33 DMPA contraception 
acceptors and 33 non-KB acceptors who met the inclusion criteria. 
Taking blood samples are done after the prospective respondent is 
given an explanation of the background, purpose, and benefits of the 
study as well as getting written approval from the research subjects.
Variables in the study
The independent variable in the study was DMPA while the dependent 
variable was FSH, progesterone, estradiol, and calcium levels.
Data analysis
Data normality test was carried out using Kolmogorov–Smirnov. To 
see the difference between dependent and independent variables on 
normally distributed data, the unpaired t-test was performed, whereas 
the test for non-normally distributed data by Mann–Whitney U-test.
RESULTS
Based on Table 1 was showed that the mean FSH levels on DMPA 
acceptor were higher than non-contraception acceptor. The result of 
statistical test shows that there is significant difference of FSH level 
between DMPA acceptor and non-acceptor contraception with p=0.001.
Based on Table 2 was showed that the mean progesterone levels on DMPA 
acceptor were lower than non-contraception acceptor. The result of 
statistical test was showed that there was significant difference of FSH level 
between DMPA acceptor and non-acceptor contraception with p=0.001.
Based on Table 3 was showed that the mean estradiol levels on DMPA 
acceptor were lower than non-contraception acceptor. The result of 
statistical test showed that there was significant difference of FSH level 
between DMPA acceptor and non-acceptor contraception with p=0.001.
Based on Table 4 was showed that the median calcium levels on DMPA 
acceptor were lower than non-contraception acceptor. The result of 
statistical test was showed that there was significant difference of FSH 
level between DMPA acceptor and non-acceptor contraception with 
p=0.001.
DISCUSSION
Differences of FSH levels on KB DMPA acceptor and non-KB 
acceptor
Table 1 shows that the mean FSH levels were higher in DMPA KB acceptor 
that is 7.61±2.77 IU/L than the mean of FSH content on non-acceptor 
of KB was 5.18±4.48 IU/L. FSH statistical test results obtained p=0.001; 
then, it could be concluded that there was a significant difference 
between KB DMPA acceptor and non-acceptor KB.
The use of DMPA progesterone would be work by decreasing GnRH 
pulsation produced in the hypothalamus, thus reducing LH release 
from the anterior pituitary. DMPA in the blood circulation will inhibit 
LH spikes in midcycle, but LH and FSH remain at the same level in the 
luteal phase [15,18].
In this research, the mean FSH levels were higher in the group using 
DMPA KB which was 7.61±2.77 IU/L compared with those not using 
KB that was 5.18±4.48 IU/L. Although DMPA could effectively suppress 
LH spikes, it could not be completely suppressed FSH so that the follicle 
continues to be stimulated to make estrogen. Estradiol would then 
stimulate the anterior pituitary to release FSH (positive feedback) so that 
the FSH level increases or remains at the same level in the luteal phase.
Differences in progesterone levels in KB DMPA and non-KB 
acceptor
The mean progesterone level on KB DMPA acceptor was 0.91±1.25 ng/ml 
while mean progesterone level in non-acceptor of family planning was 
6.59±13.38 ng/ml. The result of statistical test of progesterone obtained 
p=0.001, hence, could be concluded that there was significant difference 
between family planning DMPA acceptor and contraception acceptor.





DMPA 33 7.61±2.77 0.001
Non-acceptor contraception 33 5.18±4.48
DMPA: Depot medroxyprogesterone acetate, FSH: Follicle-stimulating hormone






DMPA 33 0.91±1.25 0.001
Non-acceptor contraception 33 6.59±13.38
DMPA: Depot medroxyprogesterone acetate
Table 3: Difference of estradiol levels on DMPA and 
non-acceptor of contraceptive
Contraception n Rerata±SD
estradiol serum  
(pg/ml)
p
DMPA 33 87.49±45.00 0.001
Non-acceptor contraception 33 137.56±60.33
DMPA: Depot medroxyprogesterone acetate
Table 4: Difference of calcium levels on DMPA and non-acceptor 
of contraceptive
Contraception n Median
calcium serum  
(mg/dl)
p
DMPA 33 8.44 0.001
Non-acceptor contraception 33 10.09
DMPA: Depot medroxyprogesterone acetate
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The mean progesterone levels were lower in contraception DMPA 
acceptor mothers compared with non-acceptor mothers. This was in 
that DMPA suppresses preovulatory LH secretion in that ovulation 
will be suppressed at least for 14 weeks. Inhibited ovulation would 
be kept low progesterone levels in the blood (<4 ng/ml) for several 
months after injection. When the level decreases (<0.1 ng/ml), then the 
ovulation may be possible [18].
The research conducted by Clark et al., on the magnitude and variability 
of estradiol and progesterone concentrations in women using DMPA, 
showed an average daily concentration of progesterone 0.14–1.1 ng/ml 
with a mean of 0.40±0.19 ng/ml [6].
The differences of estradiol levels in KB DMPA acceptor and non-
acceptor of KB
The mean estradiol content was lower in the mother of KB DMPA 
acceptor compared with the non-acceptor mother of KB. This was due 
to the use of DMPA contains high levels of progesterone which can 
inhibit the development of follicles and cause a decrease in estradiol 
levels. Long-term use of DMPA type KB may also cause serum estradiol 
levels to be lower or in the follicular phase duration [8,15].
The results of this research were in line with Pamuji et al., which examined 
the serum estrogen level of 70 women who used DMPA. All study subjects 
showed low concentrations of estradiol with an average concentration of 
<150 pg/ml; the results suggest that there was a correlation between the 
length of the use of DMPA and estradiol levels [16].
The results above were also in line with the Razali research, which 
states that DMPA family users within 1–2 years period obtained an 
average blood estradiol level of 78.69±29.76 pg/ml and the used within 
3–5 years period obtained an average level of 54.23±21.07 pg/ml. The 
decrease in estradiol levels was limited in the follicular phase, but it 
was still lower than this study where the mean estradiol blood level was 
87.494±45.004 pg/ml [17].
The differences of calcium levels on KB DMPA acceptor and non-KB 
acceptor
The effects of DMPA mechanisms that suppress ovulation lead to a 
hypoestrogenic environment that will negatively impact the absorption 
of calcium in the intestine so that bone mineral formation is impaired. 
Estrogens are essential for maintaining bone strength that regulates 
transporting calcium into bone. Without adequate estrogen, the bone 
loses calcium which is the most important component of bone [15].
Estrogen hormone deficiency can also increase calcium removal through 
the kidneys and also induce hyperparathyroidism which causes loss of 
bone mass. Without adequate levels of estrogen, bones are unable to 
absorb the right amount of calcium for bone repair, increasing bone 
mass. Decreased estrogen could be also lead to increased calcium 
excretion through the kidneys [1,9].
Akinloye et al. indicated that there is an increase in calcium resorption 
occurred in the use of oral contraceptives and injections. This 
contraception plays a role in calcium homeostasis which results in an 
increased effect of calcium mobilization from bone resulting in bone 
demineralization, which can predispose to osteoporosis [2].
The results of this research found low calcium levels in contraception 
DMPA acceptor women, whereas normal serum calcium level was 
8.9–10.5 mg/dl. Calcium levels <8.9 mg/dl were found in 29 women of 
DMPA acceptor women, and only four DMPA users were within normal 
limits. In the non-acceptors group of KB, calcium levels <8.9 mg/dl were 
found in as many as six people, whereas in the normal limit was found 
as many as 22 people and the other five people were found that it was 
valued above the normal calcium level.
Study limitations
Limitations in this study were that the researchers did not equalize the 
time and blood sampling interval after DMPA injection.
Ethical considerations
Ethical approval was granted by the Ethical Committee of Medicine, 
Andalas University of Indonesia No. 297/KEP/FK/2017.
CONCLUSION AND RECOMMENDATION
Long-term use of DMPA contraception could be affect the levels of FSH, 
progesterone, estradiol, and calcium in the blood. It was suggested that 
further studies are expected to consider the time and interval for taking 
blood samples after DMPA injection and to examine the relationship 
between estradiol levels and calcium in DMPA acceptor mothers.
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